Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

injectibles

- PMLiVE

BMS appoints new commercial leader, Davies joins Eisai and more

The latest industry movers

- PMLiVE

Sigurdur Olafsson becomes CEO of Hikma

And Said Darwazah is appointed as executive chairman

Hikma appoints group scientific officer and global head of R&D

Dr Surendera Tyagi joins the pharma group from Fresenius Kabi

Boehringer Ingelheim headquarters

Hikma pays $2.6bn for Boehringer’s US generics unit

Follows Teva’s $40.5bn purchase of Allgeran’s generics business earlier this week

- PMLiVE

Boehringer sells injectables business to Hikma for $300m

Bedford Laboratories is part of troubled Ben Venue division

- PMLiVE

Hikma pushes further into Africa with Ethiopian JV

Forms alliance with MIDROC to create HikmaCure

- PMLiVE

Hikma to retain injectables unit

Result of strategic review after acquisition interest

- PMLiVE

Injectables land-grab set to continue as Hikma reports offers

Comes just days after Mylan strikes a major deal to increase its presence in the area

- PMLiVE

Hikma expands in Egypt with EPCI acquisition

Deal in fast-growing North African market is worth about $22m

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links